Nymox Pharmaceutical Corporation (NasdaqCM:NYMX) announced that it has entered into the agreement with Paul Averback, Chief Executive Officer for a private placement of 142,857 restricted shares at an issue price of $1.75 per share for gross proceeds of $249,999.75 on November 13, 2020.